45 research outputs found
American Clinical Neurophysiology Society Guideline 1: Minimum Technical Requirements for Performing Clinical Electroencephalography
PublishedN/
Long-term Safety and Efficacy of Add-on Cannabidiol in Patients with Lennox-Gastaut Syndrome: Results of a Long- Term Open-Label Extension Trial:CBD long-term safety and efficacy in Lennox-Gastaut syndrome
Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus
Outcomes of hepatitis C virus (HCV) infection and treatment depend on viral and host genetic factors. Here we use human genome-wide genotyping arrays and new whole-genome HCV viral sequencing technologies to perform a systematic genome-to-genome study of 542 individuals who were chronically infected with HCV, predominantly genotype 3. We show that both alleles of genes encoding human leukocyte antigen molecules and genes encoding components of the interferon lambda innate immune system drive viral polymorphism. Additionally, we show that IFNL4 genotypes determine HCV viral load through a mechanism dependent on a specific amino acid residue in the HCV NS5A protein. These findings highlight the interplay between the innate immune system and the viral genome in HCV control
A New Four‐Component L*‐Dependent Model for Radial Diffusion Based on Solar Wind and Magnetospheric Drivers of ULF Waves
The outer radiation belt is a region of space comprising highly energetic
electrons. During periods of extreme space weather, the number and energy of these electrons can rapidly vary.
During these periods as the electron energies and numbers become enhanced, they can pose a threat to satellite
and space infrastructure. While we have an excellent understanding of the physical processes which drive
radiation belt electron dynamics, we still have a limited ability to model and forecast radiation belt dynamics;
this is a result of the complexity of Earth's radiation belt system. One of the key processes controlling radiation
belt dynamics is Ultra Low Frequency (ULF) wave radial diffusion. In this work we detail the development a
new model quantifying the strength of ULF wave radial diffusion in the outer radiation belt utilizing space base
observations of the electric and magnetic fields in Earth's magnetosphere. Accurately quantifying ULF wave
radial diffusion is fundamental to understanding radiation belt dynamics and any improvement or refinements
in radial diffusion models can help to provide a better understanding of the complex radiation belt system and
importantly improve hindcasts, nowcasts, and forecasts
GMAG: An open-source python package for ground-based magnetometers
Magnetometers are a key component of heliophysics research providing valuable insight into the dynamics of electromagnetic field regimes and their coupling throughout the solar system. On satellites, magnetometers provide detailed observations of the extension of the solar magnetic field into interplanetary space and of planetary environments. At Earth, magnetometers are deployed on the ground in extensive arrays spanning the polar cap, auroral and sub-auroral zone, mid- and low-latitudes and equatorial electrojet with nearly global coverage in azimuth (longitude or magnetic local time—MLT). These multipoint observations are used to diagnose both ionospheric and magnetospheric processes as well as the coupling between the solar wind and these two regimes at a fraction of the cost of in-situ instruments. Despite their utility in research, ground-based magnetometer data can be difficult to use due to a variety of file formats, multiple points of access for the data, and limited software. In this short article we review the Open-Source Python library GMAG which provides rapid access to ground-based magnetometer data from a number of arrays in a Pandas DataFrame, a common data format used throughout scientific research
Author Correction: An analysis-ready and quality controlled resource for pediatric brain white-matter research
EEGnet: A Web Platform for Collaborative EEG Research
EEG research is often impeded due to a lack of large-scale standardized data sets that can be used for training and validating algorithms. To address this issue, we have developed EEGnet, a web-based platform that enables a distributed team of experts to assemble and annotate events in large scalp EEG datasets in a streamlined fashion. EEGnet supports most features of modern digital EEG visualization software, such as multiple montages, digital filtering, and gain adjustment. It allows annotation of segments of EEG signals in single channels or annotation of epochs encompassing all channels. EEGnet supports the visualization of short EEG files and also long EEG files, up to 24 hours in length, but only for data in a 10-20 montage (with one ECG channel). Advanced visualization capabilities are provided for displaying the output of automated interpretation algorithms and comparing these results with annotations from human experts. We hope to make the EEG research community more aware of EEGnet as a means of facilitating large-scale collaborative research initiatives
American Clinical Neurophysiology Society Guideline 4: Recording Clinical EEG on Digital Media.
Digital EEG recording systems are now widely available and relatively inexpensive. They offer multiple advantages over previous analog/paper systems, such as higher fidelity recording, signal postprocessing, automated detection, and efficient data storage. This document provides guidance for the creation of digital EEG recordings including (1) documentation of patient information, (2) notation of information during the recording, (3) digital signal acquisition parameters during the recording, (4) storage of digital information, and (5) display of digital EEG signals
A phase 1b/2a study of soticlestat as adjunctive therapy in participants with developmental and/or epileptic encephalopathies.
OBJECTIVE: To evaluate the safety, tolerability, and pharmacokinetics of soticlestat, a first-in-class cholesterol 24-hydroxylase inhibitor, in adults with developmental and/or epileptic encephalopathies (DEE).
METHODS: The study comprised a 30-day, randomized, double-blind, placebo-controlled phase (Part A), followed by a 55-day open-label phase (Part B) (ClinicalTrials.gov ID: NCT03166215) . In Part A, patients with DEE and at least one bilateral motor seizure during the 4-week prospective baseline period were randomized 4:1 to receive soticlestat or placebo, in addition to their usual antiseizure medication. In Part B, all patients received open-label soticlestat. Soticlestat doses were titrated according to tolerability to a maximum of 300 mg twice daily (BID). Safety evaluations included the incidence of treatment-emergent adverse events (TEAEs). Plasma soticlestat concentrations were measured at various times for determination of multiple-dose pharmacokinetics and 24S-hydroxycholesterol (24HC). Efficacy was assessed by evaluation of changes in seizure frequency from baseline.
RESULTS: Eighteen patients (median age, 28.5 years) were enrolled and randomized, and 14 (78 %) completed the study. In Part A, TEAEs occurred in 71.4 % of soticlestat-treated patients and 100 % of placebo-treated patients. In Part B, the overall incidence of TEAEs was 68.8 %. In Part A, TEAEs that occurred in more than one patient in the soticlestat group were dysarthria (n = 3, 21.4 %), lethargy (n = 2, 14.3 %), upper respiratory tract infection (n = 2, 14.3 %), fatigue (n = 2, 14.3 %), and headache (n = 2, 14.3 %). Four patients discontinued treatment because of TEAEs, of whom two reported drug-related seizure clusters as serious TEAEs. There were no deaths. Pharmacokinetic analysis showed dose-dependent increases in systemic exposure and peak plasma soticlestat concentrations. At the end of Part B, the overall mean percent change from baseline in plasma 24HC was -80.97 %. Changes from baseline in median seizure frequency were +16.71 % and +22.16 % in the soticlestat and placebo groups, respectively, in Part A, and -36.38 % in all participants in Part B.
CONCLUSION: Soticlestat was well tolerated at doses of up to 300 mg BID and was associated with a reduction in median seizure frequency over the study duration. Further studies are warranted to assess the possible efficacy of soticlestat as adjunctive therapy in patients with DEEs such as Dravet syndrome and Lennox-Gastaut syndrome